BOYNECLARKE LLP congratulates ABK Biomedical Inc. on being awarded $2.14 Million from the Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation Fund (AIF).
Founded by interventional radiologist, Dr. Bob Abraham and materials scientists Dr. Daniel Boyd and Dr. Sharon Kehoe, ABK Biomedical Inc. is a research and development company pursuing development, production and sale of embolic agents and peripheral vascular delivery devices. ABK innovates integrated devices to simplify clinical procedures performed by interventional radiologists, with the lead system OccluRad /OccluDel, targeting hypervascular tumours including uterine fibroids. The AIF funding will support the development and commercialization of biomaterials that will simplify and enhance the delivery of chemotherapy and radiotherapy for cancer patients.
Congratulations to ABK Biomedical on your recent success!